Nanobiotix presents early lung cancer trial data at ESTRO
The data was presented at the 2026 European Society for Radiotherapy and Oncology Annual Meeting. The study evaluated the intratumoral radioenhancer in combination with concurrent chemoradiotherapy and consolidation with durvalumab.
According to the press release statement, seven patients completed the full treatment regimen. The overall response rate was 85.7%, with six of seven patients responding. Four patients achieved complete response, representing a 57.1% complete response rate. All seven patients achieved disease control, resulting in a 100% disease control rate.The positive clinical data comes as Nanobiotix shares trade at $0.09, down nearly 8% over the past week despite the promising trial results.
The study concluded that intratumoral injection of JNJ-1900 is feasible and can be performed safely in patients with stage 3 unresectable non-small cell lung cancer. The press release noted that current standard of care shows complete response rates below 5% in this patient population.
JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate achieved proof-of-concept in soft tissue sarcomas through a Phase 2/3 study in 2018.
The U.S. Food and Drug Administration granted Fast Track designation for JNJ-1900 in February 2020 for investigation in locally advanced head and neck squamous cell cancers.
